ArticleScience progress
Pauci-immune glomerulonephritis: Post-COVID kidney disease continues to reappear, a case report.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a female in her mid-70s with COVID-19 infection who developed worsening renal function along with systemic symptoms over months. The patient was initially monitored for long COVID and was referred to the nephrologist after she was found to have further worsening of her renal function. She underwent a renal biopsy and findings on light microscopy, immunofluorescence, and electron microscopy were consistent with crescentic glomerulonephritis, pauci-immune type with chronicity, and acute interstitial nephritis. These findings and a positive anti-neutrophilic cytoplasmic antibody immunofluorescence assay (ANCA IFA) and myeloperoxidase antibody confirmed myeloperoxidase-ANCA-positive pauci-immune glomerulonephritis. The patient was started on treatment with corticosteroids and Rituximab, resulting in improvement in her symptoms and renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.